



## ASX Announcement

16 October 2025

### Results of 2025 Annual General Meeting

Cambium Bio Limited (ASX:CMB) (**Cambium Bio, Cambium** or **Company**), advises that the results of its Annual General Meeting (AGM) are set out in the attached document in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) (the Act) and ASX Listing Rule 3.13.2.

All resolutions were decided by way of poll. All resolutions were carried. Details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

In accordance with ASX Listing Rule 3.13.2(f), Cambium Bio advises that more than 25% of the votes cast on Resolution 1 were against the adoption of the 2025 Remuneration Report and therefore constitutes a "first strike" under section 250U of the Act.

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

**- END -**

For further information, please contact:

Cambium Bio Limited  
Unit 2.06/31 Lexington Dr, Bella Vista, NSW 2153, Australia  
ABN 13 127 035 358  
Phone: 1300 995 098  
[www.cambium.bio](http://www.cambium.bio)

#### About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical

needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit [www.cambium.bio](http://www.cambium.bio)

**CAMBIUM BIO LIMITED**

ANNUAL GENERAL MEETING  
Thursday, 16 October, 2025

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			Result
No	Short Description	Strike Y/N/NA	For	Against	Discretionary (OpenVotes)	Abstain	For	Against	Abstain **	
01	ADOPTION OF THE REMUNERATION REPORT	Y	168,934 29.99%	193,755 34.39%	200,664 35.62%	2,113	369,598 65.61%	193,755 34.39%	2,113	Carried
02	RE-ELECTION OF DIRECTOR, CHANDRA BALA	NA	7,072,040 96.79%	32,193 0.44%	202,664 2.77%	0	7,274,704 99.56%	32,193 0.44%	0	Carried
03	RE-ELECTION OF DIRECTOR, LI CHIEN CHIU	NA	7,072,040 96.79%	32,193 0.44%	202,664 2.77%	0	7,274,704 99.56%	32,193 0.44%	0	Carried
04	RE-ELECTION OF DIRECTOR, DENESE MARKS	NA	7,071,640 96.78%	32,593 0.45%	202,664 2.77%	0	7,274,304 99.55%	32,593 0.45%	0	Carried
05	RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES LISTING RULE 7.1	NA	6,902,252 94.46%	201,981 2.76%	202,664 2.77%	0	7,104,916 97.24%	201,981 2.76%	0	Carried
06	RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES LISTING RULE 7.1A	NA	6,902,252 94.46%	201,981 2.76%	202,664 2.77%	0	7,104,916 97.24%	201,981 2.76%	0	Carried
07	APPROVAL FOR RELATED PARTY PARTICIPATION IN PLACEMENT PROF EDMUND WALLER	NA	6,784,817 96.55%	40,921 0.58%	201,714 2.87%	513	6,986,531 99.42%	40,921 0.58%	513	Carried
08	APPROVAL FOR RELATED PARTY PARTICIPATION IN PLACEMENT TERENCE WALTS	NA	7,063,749 96.68%	40,921 0.56%	201,714 2.76%	513	7,265,463 99.44%	40,921 0.56%	513	Carried

**CAMBIUM BIO LIMITED**

ANNUAL GENERAL MEETING  
Thursday, 16 October, 2025

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution Voted on at the meeting			Proxy Votes (as at proxy close)				Total votes cast in the poll (where applicable)			
No	Short Description	Strike Y/N/NA	<i>For</i>	<i>Against</i>	<i>Discretionary (OpenVotes)</i>	<i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>	<i>Result</i>
09	APPROVAL FOR RELATED PARTY OPTIONS PROF EDMUND WALLER	NA	6,783,867 96.53%	40,921 0.58%	202,664 2.88%	513	6,986,531 99.42%	40,921 0.58%	513	Carried
10	APPROVAL FOR RELATED PARTY OPTIONS TERENCE WALTS	NA	7,062,799 96.67%	40,921 0.56%	202,664 2.77%	513	7,265,463 99.44%	40,921 0.56%	513	Carried
11	APPROVAL OF ADDITIONAL PLACEMENT CAPACITY UNDER LISTING RULE 7.1A	NA	7,062,799 96.66%	41,528 0.57%	202,570 2.77%	0	7,265,369 99.43%	41,528 0.57%	0	Carried
12	APPROVAL TO ISSUE UP TO AUD\$10,000,000 WORTH OF SHARES	NA	7,063,199 96.66%	41,128 0.56%	202,570 2.77%	0	7,265,769 99.44%	41,128 0.56%	0	Carried
13	AMENDMENTS TO THE COMPANY'S CONSTITUTION	NA	7,062,799 96.77%	32,808 0.45%	202,664 2.78%	8,626	7,265,463 99.55%	32,808 0.45%	8,626	Carried

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item